Court Report

        By Sherri Oslick --

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Forest Laboratories Inc. et al. v. First Time US Generics LLC
1:13-cv-01642; filed October 2, 2013 in the District Court of Delaware

• Plaintiffs:  Forest Laboratories Inc.; Forest Laboratories Holdings Ltd.; Royalty Pharma Collection Trust
• Defendant:  First Time US Generics LLC

Infringement of U.S. Patent Nos. 6,602,911 ("Methods of Treating Fibromyalgia," issued August 5, 2003), 7,888,342 ("Methods of Treating Fibromyalgia Syndrome, Chronic Fatigue Syndrome and Pain," issued February 15, 2011), and 7,994,220 ("Milnacipran for the Long-Term Treatment of Fibromyalgia Syndrome," issued August 9, 2011), all licensed to Forest, following a Paragraph IV certification as part of First Time's filing of an ANDA to manufacture a generic version of Forest's Savella® (milnacipran hydrochloride, used in the management of fibromyalgia).  View the complaint here.

Andrulis Pharmaceuticals Corp. v. Celgene Corp.
1:13-cv-01644; filed October 2, 2013 in the District Court of Delaware

Infringement of U.S. Patent No. 6,140,346 ("Treatment of Cancer with Thalidomide Alone or in Combination with Other Anti-Cancer Agents," issued October 31, 2000) based on Celgene's promotion of its Thalomid® (thalidomide), Revlimid® (lenalidomide), and/or Alkeran® (melphalan) products for off-label use in the treatment of cancer, including multiple myeloma.  View the complaint here.

Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al.
3:13-cv-05815; filed September 30, 2013 in the District Court of New Jersey

• Plaintiffs:  Helsinn Healthcare S.A.; Roche Palo Alto LC
• Defendants:  Dr. Reddy's Laboratories, Ltd.; Dr. Reddy's Laboratories, Inc.; Sandoz Inc.; Teva Pharmaceuticals USA, Inc.; Teva Pharmaceutical Industries, Ltd.

Infringement of U.S. Patent No. 8,518,981 ("Liquid Pharmaceutical Formulations of Palonosetron," issued August 27, 2013) in conjunction with Dr. Reddy's filing of an ANDA to manufacture a generic version of Helsinn's Aloxi® (palonosetron hydrochloride intravenous solution, used to prevent chemotherapy induced nausea and vomiting).  View the complaint here.

Pfizer Inc. et al. v. Apotex Inc., et al.
1:13-cv-06962; filed September 27, 2013 in the Northern District of Illinois

• Plaintiffs:  Pfizer Inc.; Wyeth LLC; Pfizer Pharmaceuticals LLC; PF Prism C.V.; Pfizer Manufacturing Holdings LLC
• Defendants:  Apotex Inc; Apotex Corp.

Infringement of U.S. Patent No. 8,372,995 ("Crystalline Solid Forms of Trigecycline and Methods of Preparing Same," issued February 12, 2013), licensed to Pfizer, following a Paragraph IV certification as part of Apotex's filing of an ANDA to manufacture a generic version of Pfizer's Tygacil® (tigecycline injectible, used for the treatment of complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia).  View the complaint here.

Otsuka Pharmaceutical Co., Ltd. et al. v. Sandoz, Inc.
3:13-cv-05788; filed September 27, 2013 in the District Court of New Jersey

• Plaintiffs:  Otsuka Pharmaceutical Co., Ltd.; Board of Regents of The University of Texas System; University of Houston
• Defendant:  Sandoz, Inc.

Infringement of U.S. Patent Nos. 5,430,057 ("Parenteral Busulfan for Treatment of Malignant Disease," issued July 4, 1995) and 5,559,148 (same title, issued September 24, 1996), licensed to Otsuka, following a Paragraph IV certification as part of Sandoz's filing of an ANDA to manufacture a generic version of Otsuka's Busulfex® (busulfan injection, used in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia).  View the complaint here.

Galderma Laboratories, L.P. et al. v. Perrigo Israel Pharmaceuticals Ltd. et al.
3:13-cv-03930; filed September 27, 2013 in the Northern District of Texas

• Plaintiffs:  Galderma Laboratories, L.P.; Galderma SA; Galderma Research & Development SNC
• Defendants:  Perrigo Israel Pharmaceuticals Ltd.; Perrigo Co.

Infringement of U.S. Patent Nos. 7,820,186 ("Gel Composition for Once-Daily Treatment of Common Acne Comprising a Combination of Benzoyl Peroxide and Adapalene and/or Adapalene Salt," issued October 26, 2010), 7,964,202 ("Method for Treatment of Common Acne," issued June 21, 2011), 8,071,644 ("Combinations of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," issued December 6, 2011), 8,080,537 (same title, issued December 26, 2011), 8,105,618 ("Dermatological/Cosmetic Gels Comprising At Least One Retinoid and/or Retinoid Salt and Benzoyl Peroxide," issued January 31, 2012), 8,129,362 ("Combination/Association of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," issued March 6, 2012), 8,241,649 ("Dermatological/Cosmetic Gels Comprising at Least One Retinoid and/or Retinoid Salt and Benzoyl Peroxide," issued August 14, 2012), and 8,445,543 ("Combinations of Adapalene and Benzoyl Peroxide for Treating Acne Lesions," issued May 21, 2013) following a Paragraph IV certification as part of Perrigo's filing of an ANDA to manufacture a generic version of Galderma's Epiduo® Gel (adapalene and benzoyl peroxide, used to treat acne vulgaris).  View the complaint here.

Comments

[HypoGal aka HypoGal]

Thank you for the update. I had forgotten that there was a lawsuit regarding Savella I tried Savella for my fibromyalgia but it was not successful. I believe my Fibro is secondary. I developed Fibro after I was diagnosed with Sheehan's Syndrome.